Considering that PD1/PD-L1 blockade therapy is a primary ICB and that higher PD-L1 levels are associated with better ICB efficacy, we postulated that HIS-low and HIS-high tumor models could be established by manipulating PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.